<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: product development programs", fill: "#fba0e3"},
{source: "2: product development programs", target: "2: inherently risky", fill: "#fba0e3"},
{source: "2: product development programs", target: "3: failure inherent", fill: "#65000b"},
{source: "3: failure inherent", target: "3: development", fill: "#65000b"},
{source: "3: development", target: "3: product candidates based on new technologies", fill: "#65000b"},
{source: "3: failure inherent", target: "4: product candidate", fill: "#0d98ba"},
{source: "4: product candidate", target: "4: reverse certain", fill: "#0d98ba"},
{source: "4: reverse certain", target: "4: effects induced by opioids", fill: "#0d98ba"},
{source: "4: effects induced by opioids", target: "4: treat postoperative bowel dysfunction", fill: "#0d98ba"},
{source: "4: treat postoperative bowel dysfunction", target: "4: collaboration with", fill: "#0d98ba"},
{source: "4: collaboration with", target: "4: based on", fill: "#0d98ba"},
{source: "4: based on", target: "4: novel method", fill: "#0d98ba"},
{source: "4: novel method", target: "4: yet been proven", fill: "#0d98ba"},
{source: "4: yet been proven", target: "4: effective", fill: "#0d98ba"},
{source: "4: product candidate", target: "5: marketing approval", fill: "#465945"},
{source: "5: marketing approval", target: "8: Consequently ", fill: "#967117"},
{source: "8: Consequently ", target: "8: successful commercialization", fill: "#967117"},
{source: "8: successful commercialization", target: "8: products based on", fill: "#967117"},
{source: "8: products based on", target: "8: technologies", fill: "#967117"},
{source: "8: Consequently ", target: "11: commercialize", fill: "#536878"},
{source: "11: commercialize", target: "11: lead product candidate", fill: "#536878"},
{source: "11: lead product candidate", target: "11: dependence on", fill: "#536878"},
{source: "11: dependence on", target: "11: Wyeth ", fill: "#536878"},
{source: "11: Wyeth ", target: "11: exposes us", fill: "#536878"},
{source: "11: exposes us", target: "11: significant risks", fill: "#536878"},
{source: "11: commercialize", target: "14: dependent", fill: "#1e4d2b"},
{source: "14: dependent", target: "14: development", fill: "#1e4d2b"},
{source: "14: development", target: "14: regulatory", fill: "#1e4d2b"},
{source: "14: regulatory", target: "14: manufacture", fill: "#1e4d2b"},
{source: "14: manufacture", target: "14: market products containing", fill: "#1e4d2b"},
{source: "14: market products containing", target: "14: and to MNTX Our ", fill: "#1e4d2b"},
{source: "14: and to MNTX Our ", target: "14: collaboration", fill: "#1e4d2b"},
{source: "14: collaboration", target: "14: scientifically clinically", fill: "#1e4d2b"},
{source: "14: scientifically clinically", target: "14: commercially successful", fill: "#1e4d2b"},
{source: "14: dependent", target: "19: contingent", fill: "#177245"},
{source: "19: contingent", target: "19: payments from", fill: "#177245"},
{source: "19: payments from", target: "19: specified clinical regulatory", fill: "#177245"},
{source: "19: specified clinical regulatory", target: "19: commercialization milestones", fill: "#177245"},
{source: "19: commercialization milestones", target: "19: royalty payments from", fill: "#177245"},
{source: "19: royalty payments from", target: "19: regulatory approval", fill: "#177245"},
{source: "19: regulatory approval", target: "19: commercialized by", fill: "#177245"},
{source: "19: contingent", target: "40: adverse events may", fill: "#00563f"},
{source: "40: adverse events may", target: "40: testing process", fill: "#00563f"},
{source: "40: testing process", target: "40: preclinical studies may", fill: "#00563f"},
{source: "40: preclinical studies may", target: "40: inconclusive", fill: "#00563f"},
{source: "40: inconclusive", target: "40: indicative", fill: "#00563f"},
{source: "40: indicative", target: "40: human clinical trials", fill: "#00563f"},
{source: "40: human clinical trials", target: "40: potential products may", fill: "#00563f"},
{source: "40: potential products may", target: "40: characteristics", fill: "#00563f"},
{source: "40: characteristics", target: "40: preclude marketing approval", fill: "#00563f"},
{source: "40: preclude marketing approval", target: "40: commercial use", fill: "#00563f"},
{source: "40: commercial use", target: "40: reviewing test", fill: "#00563f"},
{source: "40: reviewing test", target: "40: collaborators", fill: "#00563f"},
{source: "40: collaborators", target: "40: previously", fill: "#00563f"},
{source: "40: previously", target: "40: regulators may suspend", fill: "#00563f"},
{source: "40: regulators may suspend", target: "40: terminate clinical trials", fill: "#00563f"},
{source: "40: terminate clinical trials", target: "40: participating subjects", fill: "#00563f"},
{source: "40: participating subjects", target: "40: health risks", fill: "#00563f"},
{source: "40: adverse events may", target: "42: early human clinical trials may", fill: "#00a693"},
{source: "42: early human clinical trials may", target: "42: indicative", fill: "#00a693"},
{source: "42: indicative", target: "42: later clinical trials", fill: "#00a693"},
{source: "42: early human clinical trials may", target: "54: conduct additional clinical trials", fill: "#0093af"},
{source: "54: conduct additional clinical trials", target: "54: significant revisions", fill: "#0093af"},
{source: "54: significant revisions", target: "54: clinical development", fill: "#0093af"},
{source: "54: clinical development", target: "54: development", fill: "#0093af"},
{source: "54: development", target: "54: regulatory", fill: "#0093af"},
{source: "54: regulatory", target: "54: necessary", fill: "#0093af"},
{source: "54: necessary", target: "54: product then", fill: "#0093af"},
{source: "54: product then", target: "54: Wyeth ", fill: "#0093af"},
{source: "54: Wyeth ", target: "54: codevelopment agreement", fill: "#0093af"},
{source: "54: codevelopment agreement", target: "54: agreement", fill: "#0093af"},
{source: "54: agreement", target: "54: commercialization", fill: "#0093af"},
{source: "54: commercialization", target: "54: affected products", fill: "#0093af"},
{source: "54: conduct additional clinical trials", target: "90: clinical trials", fill: "#a9ba9d"},
{source: "90: clinical trials", target: "90: additional funding", fill: "#a9ba9d"},
{source: "90: clinical trials", target: "START_HERE", fill: "#a9ba9d"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Contract_research_organization">Contract research organization</a></td>
      <td>In the life sciences, a contract research organization (CRO) is a company that provides support to the  pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis.  A CRO may provide such services as biopharmaceutical development, biologic assay development, commercialization, clinical development, clinical trials management, pharmacovigilance, outcomes research, and Real world evidence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cis-regulatory_element">Cis-regulatory element</a></td>
      <td>Cis-regulatory elements (CREs) or Cis-regulatory modules (CRMs) are regions of non-coding DNA which regulate the transcription of neighboring genes. CREs are vital components of genetic regulatory networks, which in turn control morphogenesis, the development of anatomy, and other aspects of embryonic development, studied in evolutionary developmental biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_technology">Regulatory technology</a></td>
      <td>Regulatory technology, Abrv: regtech, is a new technology that uses information technology to enhance regulatory and compliance processes. Regtech expands across all industries, including: financial services, banking, technology, retail, gaming and healthcare.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PROGENICS PHARMACEUTICALS INC      Item 1A RISK FACTORS     Our  business  and  <font color="blue">operations</font>  entail  a variety of <font color="blue">serious risks</font> and     <font color="blue">uncertainties</font>, including those described below</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">development</font> programs</font> are <font color="blue">inherently risky</font></td>
    </tr>
    <tr>
      <td>We  are subject to the risks of <font color="blue">failure inherent</font> in the <font color="blue">development</font> of     <font color="blue"><font color="blue">product candidate</font>s <font color="blue">based on</font> new <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>Our MNTX <font color="blue">product candidate</font>,     which is designed to <font color="blue">reverse certain</font> side <font color="blue">effects induced by opioids</font> and to     treat post-operative bowel <font color="blue">dysfunction</font> and is being developed through a     <font color="blue"><font color="blue">collaboration</font> with</font> Wyeth, is <font color="blue">based on</font> a <font color="blue">novel method</font> of action that has not     <font color="blue">yet been proven</font> to be safe or <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>No drug with MNTX’s method of     action has ever received <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>Additionally, some of our HIV     <font color="blue">product candidate</font>s are designed to be <font color="blue">effective</font> by blocking viral entry, and     our GMK <font color="blue">product candidate</font> is designed to be a <font color="blue">therapeutic cancer vaccine</font></td>
    </tr>
    <tr>
      <td>To     our knowledge, no drug designed to treat HIV infection by blocking viral     entry  (<font color="blue">with one exception</font>) and <font color="blue">no cancer therapeutic vaccine</font> has been     approved  for marketing in the US Our other research and <font color="blue">development</font>     programs, and those <font color="blue">conducted through</font> PSMA LLC, <font color="blue">involve similarly novel</font>     approaches to <font color="blue">human therapeutics</font></td>
    </tr>
    <tr>
      <td>Consequently, there is little precedent     for the <font color="blue">successful <font color="blue">commercialization</font></font> of products <font color="blue">based on</font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>There are a number of <font color="blue"><font color="blue">technological</font> challenges</font> that we <font color="blue">must overcome</font> to     complete most of our <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We may not be able to develop     <font color="blue">successfully</font> any of our products</td>
    </tr>
    <tr>
      <td>We have granted to Wyeth the exclusive rights to develop and <font color="blue">commercialize</font>     MNTX, our lead <font color="blue">product candidate</font>, and our resulting <font color="blue">dependence on</font> <font color="blue">Wyeth     </font><font color="blue">exposes us</font> to <font color="blue"><font color="blue">significant</font> risks</font></td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">December </font></font>2005, we <font color="blue">entered into</font> a license and co-<font color="blue">development</font> <font color="blue">agreement</font>     with  Wyeth</td>
    </tr>
    <tr>
      <td>Under  this <font color="blue">agreement</font>, we granted to Wyeth the exclusive     worldwide  right  to  develop and <font color="blue">commercialize</font> MNTX, our <font color="blue">lead product</font>     candidate</td>
    </tr>
    <tr>
      <td>As a result, we are <font color="blue">dependent</font> on Wyeth to perform and fund     <font color="blue">development</font>, including <font color="blue">clinical testing</font>, to make certain <font color="blue">regulatory</font> filings     and to <font color="blue">manufacture</font> and <font color="blue">market products containing</font> MNTX Our <font color="blue">collaboration</font>     with Wyeth may not be scientifically, clinically or <font color="blue">commercially successful</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">revenues from</font> the sale of MNTX, if approved for sale by the FDA, will     depend  <font color="blue">almost <font color="blue">entirely on</font></font> the efforts of Wyeth</td>
    </tr>
    <tr>
      <td>Wyeth has <font color="blue">significant</font>     <font color="blue">discretion</font> in determining the efforts and resources it applies to sales of     the MNTX products and may not be <font color="blue">effective</font> in <font color="blue">marketing such products</font></td>
    </tr>
    <tr>
      <td>In     addition, Wyeth is a large, <font color="blue">diversified pharmaceutical company with global</font>     <font color="blue">operations</font> and its own corporate objectives, which may not be <font color="blue">consistent</font>     with our <font color="blue">best interests</font></td>
    </tr>
    <tr>
      <td>For example, Wyeth may change its <font color="blue">strategic focus</font>     or pursue alternative <font color="blue">technologies</font> in a manner that results in reduced     revenues  to us</td>
    </tr>
    <tr>
      <td>In addition, we will receive milestone and <font color="blue">contingent</font>     <font color="blue">payments from</font> Wyeth only if MNTX achieves specified clinical, <font color="blue">regulatory</font> and     <font color="blue"><font color="blue">commercialization</font> <font color="blue">milestones</font></font>, and we will receive royalty <font color="blue">payments from</font>     Wyeth only if MNTX receives <font color="blue">regulatory</font> approval and is <font color="blue">commercialize</font>d by     Wyeth</td>
    </tr>
    <tr>
      <td>We may not receive any milestone, <font color="blue">contingent</font> or royalty <font color="blue">payments from</font> Wyeth</td>
    </tr>
    <tr>
      <td>The  Collaboration  Agreement extends, unless terminated earlier, on a     country-by-country and product-by-product basis, until the last to expire     royalty period, as defined, for any product</td>
    </tr>
    <tr>
      <td><font color="blue">Progenics </font><font color="blue">may terminate</font> the     <font color="blue">Collaboration Agreement </font>at any time upon 90 days of written notice to <font color="blue">Wyeth     </font>(30 days in the case of breach of a payment obligation) upon material breach     that is not cured</td>
    </tr>
    <tr>
      <td>Wyeth may, with or without cause, following the second     <font color="blue">anniversary</font>  of  the  first  commercial sale, as defined, of the first     <font color="blue">commercial product</font> in the US, terminate the <font color="blue">Collaboration Agreement </font>by     providing <font color="blue">Progenics </font>with at least 360 days prior written notice of such     <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>Wyeth <font color="blue">may also terminate</font> the <font color="blue">agreement</font> (i) upon 30 days written     notice <font color="blue">following one</font> or more <font color="blue">serious safety</font> or <font color="blue">efficacy issues</font> that arise,     as defined, and (ii) at any time, upon 90 days written notice of a material     breach that is not cured by Progenics</td>
    </tr>
    <tr>
      <td>Upon <font color="blue">termination</font> of the Collaboration     Agreement, the ownership of the license we granted to Wyeth <font color="blue">will <font color="blue">depend on</font></font>     the party that initiates the <font color="blue">termination</font> and the reason for the <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">relationship</font> with</font> Wyeth were to terminate, we would have to either     <font color="blue">enter into</font> a license and co-<font color="blue">development</font> <font color="blue">agreement</font> with another party or     develop and <font color="blue">commercialize</font> MNTX ourselves</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">enter into</font>     such an <font color="blue">agreement</font> with another <font color="blue">suitable company on</font> acceptable terms or at     all</td>
    </tr>
    <tr>
      <td>To develop and <font color="blue">commercialize</font> MNTX on our own, we would have to develop     a  sales and <font color="blue">marketing organization</font> and a <font color="blue"><font color="blue">distribution</font> infrastructure</font>,     neither of which we currently have</td>
    </tr>
    <tr>
      <td><font color="blue">Developing </font>these <font color="blue">resources would</font> be an     expensive and <font color="blue">lengthy process</font> and would have a material adverse effect on     our revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Moreover, a <font color="blue">termination</font> of our <font color="blue"><font color="blue">relationship</font> with</font> Wyeth could seriously     compromise  the  <font color="blue">development</font>  program  for MNTX For example, we could     experience <font color="blue">significant</font> delays in the <font color="blue">development</font> of MNTX and would have to     assume full funding and other <font color="blue">responsibility</font> for further <font color="blue">development</font> and     <font color="blue">eventual <font color="blue">commercialization</font></font></td>
    </tr>
    <tr>
      <td>Any of these outcomes would result in delays in our ability to distribute     MNTX and <font color="blue">would increase</font> our expenses, which would have a material adverse     effect on our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">collaboration</font> with</font> Wyeth is multi-faceted and involves a <font color="blue">complex sharing</font>     of control over decisions, responsibilities, costs and benefits</td>
    </tr>
    <tr>
      <td>There are     <font color="blue">numerous potential sources</font> of dis<font color="blue">agreement</font> between us and Wyeth, including     <font color="blue">with respect</font> to product <font color="blue">development</font>, marketing strategies, <font color="blue">manufacturing</font> and     supply  issues and rights relating to <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>Wyeth has     <font color="blue">significant</font>ly greater financial and <font color="blue">managerial resources than</font> we do, which     it <font color="blue">could draw upon</font> in the event of a dispute</td>
    </tr>
    <tr>
      <td>A dis<font color="blue">agreement</font> between <font color="blue">Wyeth     </font>and us could lead to lengthy and expensive <font color="blue">litigation</font> or other dispute     <font color="blue">resolution proceedings as well as</font> to extensive financial and operational     <font color="blue">consequences</font> to us, and have a material adverse effect on our business,     results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________       [44]Table of Contents     If testing does not <font color="blue">yield successful</font> results, our <font color="blue">products will</font> not be     approved</td>
    </tr>
    <tr>
      <td>We will need to obtain <font color="blue">regulatory</font> approval before we can market our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>To obtain <font color="blue">marketing approval</font> from <font color="blue">regulatory</font> <font color="blue">authorities</font>, we or     our <font color="blue"><font color="blue"><font color="blue">collaborator</font>s</font> must demonstrate</font> a product’s safety and <font color="blue">efficacy through</font>     extensive preclinical and <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>Numerous <font color="blue">adverse events may</font>     arise  during,  or  as a result of, the <font color="blue">testing process</font>, including the     following:                                                ·       the results of <font color="blue">pre<font color="blue">clinical studies</font> may</font> be <font color="blue">in<font color="blue">conclusive</font></font>, or they may not be     <font color="blue">indicative</font> of results that will be obtained in <font color="blue">human <font color="blue">clinical trials</font></font>;                                                ·       <font color="blue">potential <font color="blue">products may</font></font> not have the desired efficacy or may have undesirable     side effects or other <font color="blue">characteristics</font> that preclude <font color="blue">marketing approval</font> or     limit their <font color="blue">commercial use</font> if approved;                                                ·       after <font color="blue">reviewing test</font> results, we or our <font color="blue"><font color="blue">collaborator</font>s</font> may abandon projects,     which we <font color="blue">previously</font> believed to be promising; and                                                ·       we, our <font color="blue"><font color="blue">collaborator</font>s</font> or <font color="blue"><font color="blue">regulators</font> may suspend</font> or <font color="blue">terminate <font color="blue">clinical trials</font></font>     if we or they believe that the <font color="blue">participating subjects</font> or patients are being     exposed to unacceptable <font color="blue">health risks</font></td>
    </tr>
    <tr>
      <td>Results attained     in early <font color="blue">human <font color="blue">clinical trials</font></font> may not be <font color="blue">indicative</font> of results that are     obtained in <font color="blue">later <font color="blue">clinical trials</font></font></td>
    </tr>
    <tr>
      <td>In addition, many of our products, such     as  PRO  140 and <font color="blue">the PSMA </font><font color="blue">product candidate</font>s, are at an <font color="blue">early stage</font> of     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">successful <font color="blue">commercialization</font></font> of <font color="blue">early stage</font> <font color="blue">products will</font>     require <font color="blue">significant</font> further research, <font color="blue">development</font>, testing, approvals by     <font color="blue">regulators</font>  and <font color="blue"><font color="blue">additional</font> <font color="blue">investment</font></font></td>
    </tr>
    <tr>
      <td>Our products in the research or     preclinical <font color="blue">development</font> stage may not yield results that <font color="blue">would permit</font> or     justify <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue"><font color="blue">adequately</font> demonstrate</font> the safety     and efficacy of a product under <font color="blue">development</font> would delay or <font color="blue">prevent marketing</font>     approval of the product, <font color="blue">which could</font> <font color="blue">adversely</font> affect our operating results     and <font color="blue">credibility</font></td>
    </tr>
    <tr>
      <td>We  have <font color="blue">successfully</font> completed two pivotal phase 3 <font color="blue">clinical trials</font> of     <font color="blue">subcutaneous</font>  MNTX for the treatment of opioid-induced <font color="blue">constipation</font> in     patients  with  advanced  <font color="blue">medical illness</font></td>
    </tr>
    <tr>
      <td>We are now working with our     <font color="blue">collaborator</font> Wyeth to submit <font color="blue">a New Drug Application to the US Food </font>and     <font color="blue">Drug Administration </font>to market <font color="blue">subcutaneous</font> MNTX We also have <font color="blue">successfully</font>     completed a phase 2 clinical trial of <font color="blue">intravenous</font> MNTX in patients at risk     for post-operative bowel <font color="blue">dysfunction</font></td>
    </tr>
    <tr>
      <td>Based on our end of phase 2 meeting     with the FDA, we are planning a phase 3 clinical program for treatment of     post-operative bowel <font color="blue">dysfunction</font></td>
    </tr>
    <tr>
      <td>We had completed phase 1 <font color="blue">clinical trials</font>     of oral MNTX in healthy volunteers prior to our <font color="blue">Collaboration Agreement </font>with     Wyeth</td>
    </tr>
    <tr>
      <td>Wyeth is responsible for the worldwide <font color="blue">development</font> of oral MNTX and     will  conduct  <font color="blue">additional</font> <font color="blue">clinical trials</font> of oral MNTX in chronic pain     patients who experience opioid-induced <font color="blue">constipation</font></td>
    </tr>
    <tr>
      <td>If the results of any of these <font color="blue">ongoing trials</font> are not satisfactory, or if we     <font color="blue">encounter problems enrolling patients</font>, or if clinical trial supply issues or     other <font color="blue"><font color="blue">difficult</font>ies</font> arise, our entire MNTX <font color="blue">development</font> program could be     <font color="blue"><font color="blue">adversely</font> affected</font>, resulting in delays in commencing or completing clinical     trials or in making our <font color="blue">regulatory</font> filing for <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>The need     to  conduct <font color="blue">additional</font> <font color="blue">clinical trials</font> or <font color="blue">significant</font> revisions to our     clinical <font color="blue">development</font> plan would lead to delays in filing for the <font color="blue">regulatory</font>     approvals  <font color="blue">necessary</font> to market MNTX If the <font color="blue">clinical trials</font> indicate a     serious problem with the safety or efficacy of an MNTX product, then <font color="blue">Wyeth     </font>has the right under our license and co-<font color="blue">development</font> <font color="blue">agreement</font> to terminate     the  <font color="blue">agreement</font>  or to stop the <font color="blue">development</font> or <font color="blue">commercialization</font> of the     <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Since MNTX </font>is our <font color="blue">most clinically advanced product</font>, any     setback of these <font color="blue">types would</font> have a material adverse effect on our stock     price and business</td>
    </tr>
    <tr>
      <td>We also have two ongoing pivotal phase 3 <font color="blue">clinical trials</font> for GMK In May     2000, our <font color="blue">collaborating research cooperative</font> group in one of these trials,     ECOG, recommended to <font color="blue">clinical investigators participating</font> in the trial that     they <font color="blue">discontinue <font color="blue">administer</font>ing</font> GMK, and as a result that trial did not     complete patient dosing as contemplated by the initial trial protocol</td>
    </tr>
    <tr>
      <td>A     second pivotal phase 3 trial for GMK was initiated in May 2001 and full     <font color="blue">enrollment</font> of 1cmam314 patients has been completed</td>
    </tr>
    <tr>
      <td>We expect to assess the     recurrence of cancer and <font color="blue">overall survival</font> of the <font color="blue">study patients over</font> the     <font color="blue">next <font color="blue">several years</font></font></td>
    </tr>
    <tr>
      <td>If the results of either <font color="blue">of the GMK </font>trials are not     satisfactory, we may need to conduct <font color="blue">additional</font> <font color="blue">clinical trials</font> or abandon     our GMK program</td>
    </tr>
    <tr>
      <td>If the results of     our phase 1b study with PRO 140 or the preclinical and <font color="blue">clinical studies</font>     involving <font color="blue">the PSMA </font>vaccine and antibody <font color="blue">candidates</font> are not satisfactory, we     would need to <font color="blue">reconfigure</font> our <font color="blue">clinical trial programs</font> to conduct <font color="blue">additional</font>     trials or abandon the <font color="blue">program involved</font></td>
    </tr>
    <tr>
      <td>We have incurred substantial <font color="blue">losses since</font> our inception</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31,     2005, we had an <font color="blue">accumulated deficit</font> of dlra188dtta7 million</td>
    </tr>
    <tr>
      <td>We have <font color="blue">derived no</font>     <font color="blue">significant</font> <font color="blue">revenues from</font> product sales or royalties</td>
    </tr>
    <tr>
      <td>We do not expect to     achieve <font color="blue">significant</font> product sales or <font color="blue">royalty revenue</font> for a number of years,     if  ever,  other than potential <font color="blue">revenues from</font> MNTX We expect to incur     <font color="blue">additional</font>  operating  losses  in  the  future,  which  <font color="blue">could increase</font>     <font color="blue">significant</font>ly as we expand our <font color="blue">clinical trial programs</font> and other product     <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Our ability to achieve and sustain <font color="blue">profitability</font> is <font color="blue">dependent</font> in part on     obtaining   <font color="blue">regulatory</font>  approval  to  market  our  products  and  then     <font color="blue">commercializing</font>, either alone or <font color="blue">with others</font>, our products</td>
    </tr>
    <tr>
      <td>We may not be     able to develop and <font color="blue">commercialize</font> products</td>
    </tr>
    <tr>
      <td>Moreover, our <font color="blue">operations</font> may not     be  profitable  even  if  any  of  our  products under <font color="blue">development</font> are     <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>We  are likely to need <font color="blue">additional</font> financing, but our access to capital     funding is uncertain</td>
    </tr>
    <tr>
      <td>As  of <font color="blue">December </font>31, 2005, we had cash, cash equivalents and marketable     securities, including non-current portion, totaling dlra173dtta1 million</td>
    </tr>
    <tr>
      <td>In     <font color="blue">December </font>2005, we received a dlra60 million upfront payment from Wyeth in     <font color="blue">connection</font> with the signing of the license and co-<font color="blue">development</font> <font color="blue">agreement</font>     relating to MNTX During the year ended <font color="blue">December </font>31, 2005, we had a net loss     of dlra69dtta4 million and <font color="blue">cash provided by</font> operating <font color="blue">activities</font> was dlra11dtta1 million     during the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Under  our  <font color="blue">agreement</font>  with Wyeth, Wyeth is responsible for all future     <font color="blue">development</font> and <font color="blue">commercialization</font> costs relating to MNTX starting January 1,     2006</td>
    </tr>
    <tr>
      <td>As a result, we expect that our spending on MNTX in 2006 and beyond     will drop <font color="blue">significant</font>ly from the amounts expended in 2005</td>
    </tr>
    <tr>
      <td>With regard to our other <font color="blue">product candidate</font>s, however, we expect that we will     continue to incur <font color="blue">significant</font> <font color="blue">expenditures</font> for their <font color="blue">development</font> and we do     not have <font color="blue">committed external sources</font> of funding for most of these projects</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">expenditures</font> will</font> be <font color="blue">funded from</font> our <font color="blue">cash on hand</font>, or we may seek     <font color="blue">additional</font> <font color="blue">external funding</font> for these <font color="blue">expenditures</font>, most likely through     <font color="blue">collaborative</font> <font color="blue">agreement</font>s, or other license or sale transactions, with one or     more pharmaceutical companies, through the issuance and sale of securities     or through <font color="blue">additional</font> <font color="blue"><font color="blue">government</font> grants</font> or contracts</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict with</font>     any <font color="blue">certainty</font> when we will need <font color="blue">additional</font> funds or how much we will need or     if <font color="blue">additional</font> funds will be available to us</td>
    </tr>
    <tr>
      <td>Our need for <font color="blue">future funding</font>     <font color="blue">will <font color="blue">depend on</font></font> numerous factors, many of which are outside our control</td>
    </tr>
    <tr>
      <td>Our access to <font color="blue">capital funding</font> is uncertain</td>
    </tr>
    <tr>
      <td>We may not be able to obtain     <font color="blue">additional</font> funding on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to raise     <font color="blue">additional</font> capital on terms reasonably acceptable to <font color="blue">us would seriously</font>     <font color="blue">jeopardize</font> the <font color="blue">future success</font> of our business</td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise funds by issuing</font> and <font color="blue">selling securities</font>, it may be on terms that     are not favorable to our <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> funds     <font color="blue">by selling equity securities</font>, our <font color="blue">current <font color="blue">stockholders</font> will</font> be diluted, and     <font color="blue">new investors could</font> have rights superior to our <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>If we     <font color="blue">raise funds by selling debt securities</font>, we could be subject to <font color="blue">restrictive</font>     covenants and <font color="blue">significant</font> repayment <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">clinical trials</font> could</font> take <font color="blue">longer than</font> we expect</td>
    </tr>
    <tr>
      <td>Although for planning purposes we forecast the <font color="blue">commencement</font> and <font color="blue">completion</font>     of <font color="blue">clinical trials</font>, and have included many of those forecasts in reports     filed  with <font color="blue">the Securities and Exchange Commission </font>and in other public     <font color="blue"><font color="blue">disclosure</font>s</font>, the <font color="blue">actual timing</font> of these events can <font color="blue">vary dramatically</font></td>
    </tr>
    <tr>
      <td>For     example, we have experienced delays in our MNTX clinical <font color="blue">development</font> program     in the past as a result of <font color="blue">slower than</font> anticipated patient <font color="blue">enrollment</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">delays may recur</font></td>
    </tr>
    <tr>
      <td>Delays can be caused by, among other things:                                               ·       deaths or other <font color="blue">adverse medical events involving patients</font> or subjects in our     <font color="blue">clinical trials</font>;                                              ·       <font color="blue">regulatory</font> or <font color="blue">patent issues</font>;                                               ·       interim or final results of <font color="blue">ongoing <font color="blue">clinical trials</font></font>;                                              ·       failure to <font color="blue">enroll clinical sites as</font> expected;                                               ·       <font color="blue">competition</font> for <font color="blue">enrollment</font> from <font color="blue">clinical trials</font> <font color="blue">conducted by</font> others in     similar <font color="blue">indications</font>;                                               ·       <font color="blue">scheduling conflicts with participating clinicians</font> and clinical     <font color="blue"><font color="blue">institution</font>s</font>; and                                               ·       <font color="blue"><font color="blue">manufacturing</font> problems</font></td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________       [46]Table of Contents     In addition, we may need to delay or suspend our <font color="blue">clinical trials</font> if we are     unable to obtain <font color="blue">additional</font> funding when needed</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials involving</font>     our <font color="blue">product candidate</font>s may not commence or be completed <font color="blue">as forecasted</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>work  on  <font color="blue">the PSMA </font>projects continues, our <font color="blue">clinical programs</font>     involving PSMA LLC <font color="blue">could also</font> be delayed by dis<font color="blue">agreement</font>s between <font color="blue">Cytogen     </font>and us <font color="blue">concerning</font> funding <font color="blue">development</font> programs or other matters</td>
    </tr>
    <tr>
      <td><font color="blue">PSMA LLC     </font>currently has no approved 2006 budget or work plan because we and <font color="blue">Cytogen     </font>have not yet reached <font color="blue">agreement</font> <font color="blue">with respect</font> to a number of matters relating     to <font color="blue">PSMA LLC     </font>Moreover, we have limited experience in conducting <font color="blue">clinical trials</font>, and we     <font color="blue">rely on others</font> to conduct, supervise or monitor some or all aspects of some     of  our  <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>In addition, certain <font color="blue">clinical trials</font> for our     <font color="blue">products may</font> be <font color="blue">conducted by</font> <font color="blue">government</font>-sponsored agencies, and <font color="blue">consequently</font>     will be <font color="blue">dependent</font> on <font color="blue">government</font>al participation and funding</td>
    </tr>
    <tr>
      <td>Under our     <font color="blue">agreement</font> with Wyeth relating to MNTX, Wyeth has the <font color="blue">responsibility</font> to     conduct some of the <font color="blue">clinical trials</font> for that <font color="blue">product candidate</font>, including     all <font color="blue">trials outside</font> of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We will have <font color="blue">less control over</font> the     timing and other aspects of these <font color="blue">clinical trials</font> than if we <font color="blue">conducted them</font>     <font color="blue">entirely on</font> our own</td>
    </tr>
    <tr>
      <td>As a result of these and other factors, our <font color="blue">clinical trials</font> may not commence     or be completed as we expect or may not be conducted <font color="blue">successfully</font>, in which     event  investors’ confidence in our ability to develop <font color="blue">products may</font> be     impaired and our <font color="blue">stock price may decline</font></td>
    </tr>
    <tr>
      <td>We  are  subject to extensive regulation, which can be costly and time     consuming and can subject us to <font color="blue">unanticipated fines</font> and delays</td>
    </tr>
    <tr>
      <td>We and our products are subject to <font color="blue">comprehensive</font> regulation by the FDA in     the US and by comparable <font color="blue">authorities</font> in other countries</td>
    </tr>
    <tr>
      <td>These national     agencies and other federal, state and local entities regulate, among other     things, the preclinical and <font color="blue">clinical testing</font>, safety, approval, <font color="blue">manufacture</font>,     labeling,  marketing, export, storage, record keeping, <font color="blue">advertising</font> and     promotion of <font color="blue">pharmaceutical products</font></td>
    </tr>
    <tr>
      <td>If we violate <font color="blue">regulatory</font> <font color="blue">requirements</font>     at any stage, whether before or after <font color="blue">marketing approval</font> is obtained, we may     be subject to <font color="blue">forced removal</font> of a <font color="blue">product from</font> the market, product seizure,     civil and <font color="blue">criminal penalties</font> and other adverse <font color="blue">consequences</font></td>
    </tr>
    <tr>
      <td>Our products do not yet have, and may never obtain, the <font color="blue">regulatory</font> approvals     needed for marketing</td>
    </tr>
    <tr>
      <td>None of our products has been approved by applicable <font color="blue">regulatory</font> <font color="blue">authorities</font>     for marketing</td>
    </tr>
    <tr>
      <td>The process of obtaining FDA and foreign <font color="blue">regulatory</font> approvals     often takes many years and can vary <font color="blue">substantially</font> <font color="blue">based upon</font> the type,     <font color="blue">complexity</font> and novelty of the <font color="blue">products involved</font></td>
    </tr>
    <tr>
      <td>We have had only limited     experience  in  filing and <font color="blue">pursuing <font color="blue">applications</font></font> and other <font color="blue">submissions</font>     <font color="blue">necessary</font> to gain <font color="blue">marketing approval</font>s</td>
    </tr>
    <tr>
      <td>Our products under <font color="blue">development</font> may     never obtain the <font color="blue">marketing approval</font> from the FDA or any other <font color="blue">regulatory</font>     authority <font color="blue">necessary</font> for <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Even if our products receive <font color="blue">regulatory</font> approval:                                               ·       they might not obtain labeling claims <font color="blue">necessary</font> to make the product     <font color="blue">commercially viable</font> (in general, labeling claims define the medical     <font color="blue">conditions</font> for which a <font color="blue">drug product may</font> be marketed, and are therefore very     important to the <font color="blue">commercial success</font> of a product);                                               ·       we or our <font color="blue"><font color="blue">collaborator</font>s</font> might be required to undertake post-marketing trials     to verify the product’s efficacy or safety;                                               ·       we, our <font color="blue"><font color="blue">collaborator</font>s</font> or <font color="blue">others might</font> identify side effects after the     product is on the market, or we or our <font color="blue"><font color="blue">collaborator</font>s</font> might experience     <font color="blue"><font color="blue">manufacturing</font> problems</font>, either of <font color="blue">which could</font> result in subsequent     withdrawal of <font color="blue">marketing approval</font>, reformulation of the product, <font color="blue">additional</font>     pre<font color="blue">clinical testing</font> or <font color="blue">clinical trials</font>, changes in labeling of the product     or the need for <font color="blue">additional</font> marketing <font color="blue">applications</font>; and                                               ·       we and our <font color="blue"><font color="blue">collaborator</font>s</font> will be subject to ongoing FDA <font color="blue">obligations</font> and     continuous <font color="blue">regulatory</font> review</td>
    </tr>
    <tr>
      <td>If  our <font color="blue">products fail</font> to receive <font color="blue">marketing approval</font> or lose <font color="blue">previously</font>     received approvals, our financial results would be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________       [47]Table of Contents     Even if our products obtain <font color="blue">marketing approval</font>, they might not be accepted     in the marketplace</td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of our <font color="blue">products will</font> depend upon their <font color="blue">acceptance by</font>     the <font color="blue">medical community</font> and <font color="blue">third party</font> payors as clinically useful, cost     <font color="blue">effective</font> and safe</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">health care</font> providers</font> believe that patients can be     managed <font color="blue">adequately</font> with alternative, currently available therapies, they may     not prescribe our products, especially if the <font color="blue">alternative therapies</font> are     viewed as more <font color="blue">effective</font>, as having a <font color="blue">better safety</font> or tolerability profile,     as being more <font color="blue">convenient</font> to the patient or <font color="blue"><font color="blue">health care</font> providers</font> or as being     less  expensive</td>
    </tr>
    <tr>
      <td>For <font color="blue"><font color="blue">pharmaceuticals</font> <font color="blue">administer</font>ed</font> in an <font color="blue">institution</font>al     setting, the ability of the <font color="blue">institution</font> to be <font color="blue"><font color="blue">adequately</font> reimbursed could</font>     also  play  a <font color="blue">significant</font> role in demand for our products</td>
    </tr>
    <tr>
      <td>Even if our     products obtain <font color="blue">marketing approval</font>, they may not achieve <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>If any of our products do not achieve <font color="blue">market acceptance</font>, we <font color="blue">will likely lose</font>     our <font color="blue">entire <font color="blue">investment</font></font> in that product</td>
    </tr>
    <tr>
      <td><font color="blue">Marketplace </font><font color="blue">acceptance will depend</font> in part on <font color="blue">competition</font> in our industry,     which is intense</td>
    </tr>
    <tr>
      <td>The extent to which any of our products achieves <font color="blue">market acceptance</font> will     <font color="blue"><font color="blue">depend on</font> competitive factors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in our industry is intense, and     it is <font color="blue">accentuated</font> by the rapid pace of <font color="blue">technological</font> <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>There are     products currently in the market that <font color="blue">will compete with</font> the products that we     are developing, including AIDS drugs and <font color="blue">chemotherapy drugs</font> for treating     cancer</td>
    </tr>
    <tr>
      <td>As described below, <font color="blue">Adolor Corporation </font>is developing a drug that     <font color="blue">would compete with</font> MNTX Many of our <font color="blue">competitors</font> have <font color="blue">substantially</font> greater     research  and  <font color="blue">development</font>  <font color="blue">capabilities</font>  and  experience  and greater     <font color="blue">manufacturing</font>, marketing, financial and <font color="blue">managerial resources than</font> we do</td>
    </tr>
    <tr>
      <td>These <font color="blue">competitors</font> may develop products that are superior to those we are     developing  and render our products or <font color="blue">technologies</font> non-competitive or     obsolete</td>
    </tr>
    <tr>
      <td>If our <font color="blue">product candidate</font>s receive <font color="blue">marketing approval</font> but cannot     compete <font color="blue">effective</font>ly in the marketplace, our operating results and financial     <font color="blue">position would suffer</font></td>
    </tr>
    <tr>
      <td>One or more <font color="blue">competitors</font> developing an <font color="blue">opioid <font color="blue">antagonist</font></font> may reach the market     ahead of us and <font color="blue">adversely</font> affect the market potential for MNTX     We are aware that Adolor Corporation, in <font color="blue"><font color="blue">collaboration</font> with</font> Glaxo Group     Limited, or Glaxo, a subsidiary <font color="blue">of GlaxoSmithKline </font>plc, is developing an     <font color="blue">opioid <font color="blue">antagonist</font></font>, Entereg™ (alvimopan), for post-operative ileus, which has     completed phase 3 <font color="blue">clinical trials</font>, and for opioid-induced bowel <font color="blue">dysfunction</font>,     which is in phase 3 <font color="blue">clinical trials</font> Post-operative ileus is a condition     similar to post-operative bowel <font color="blue">dysfunction</font>, a condition for which we are     developing  MNTX Entereg is <font color="blue">further along</font> in the clinical <font color="blue">development</font>     <font color="blue">process than</font> MNTX, and <font color="blue">Adolor Corporation </font>has received an <font color="blue">approvable letter</font>     from  the  US Food and <font color="blue">Drug Administration </font>for Entereg regarding the     treatment of post-operative ileus</td>
    </tr>
    <tr>
      <td>Additionally, it has been reported that a     European <font color="blue">specialty pharmaceutical company</font> is in clinical <font color="blue">development</font> of an     <font color="blue">oral formulation</font> of <font color="blue">methylnaltrexone</font> for use in opioid-induced <font color="blue">constipation</font></td>
    </tr>
    <tr>
      <td>If either of these products reaches the market before MNTX, it could achieve     a <font color="blue">significant</font> competitive advantage relative to our product</td>
    </tr>
    <tr>
      <td>In any event,     the considerable marketing and sales <font color="blue">capabilities</font> of Glaxo may impair our     ability to penetrate the market</td>
    </tr>
    <tr>
      <td>Under the terms of our <font color="blue"><font color="blue">collaboration</font> with</font> Wyeth <font color="blue">with respect</font> to MNTX, <font color="blue">Wyeth     </font>will  develop  the  oral form of MNTX worldwide</td>
    </tr>
    <tr>
      <td>We will lead the US     <font color="blue">development</font> of the <font color="blue">subcutaneous</font> and <font color="blue">intravenous</font> forms of MNTX, while <font color="blue">Wyeth     </font>will lead <font color="blue">development</font> of these <font color="blue">parenteral products outside</font> the US <font color="blue">Wyeth     </font>and we will pursue an integrated strategy to optimize worldwide <font color="blue">development</font>,     <font color="blue">regulatory</font> approval, and commercial launch of the three MNTX products, which     <font color="blue">may impact timelines</font> for the <font color="blue">development</font> of MNTX <font color="blue">previously</font> disclosed by us</td>
    </tr>
    <tr>
      <td><font color="blue">Decisions </font>regarding the timelines for <font color="blue">development</font> of the three MNTX products     will be made by a <font color="blue">Joint Development Committee </font><font color="blue">formed under</font> the terms of the     license and co-<font color="blue">development</font> <font color="blue">agreement</font>, consisting of <font color="blue">members from both</font> <font color="blue">Wyeth     </font>and Progenics</td>
    </tr>
    <tr>
      <td>Disputes with Cytogen <font color="blue">could delay</font> or halt our PSMA programs</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> programs relating to vaccine and antibody     immunotherapeutics <font color="blue">based on</font> PSMA are <font color="blue">conducted through</font> PSMA LLC, a joint     venture between Cytogen Corporation and us</td>
    </tr>
    <tr>
      <td>This is a 50/50 joint venture,     meaning that our <font color="blue">ownership rights</font> in the programs, funding <font color="blue">obligations</font> and     governance  rights  are  equal</td>
    </tr>
    <tr>
      <td>As  a result, for PSMA LLC to operate     <font color="blue">efficiently</font>, and for the research and <font color="blue">development</font> programs to be <font color="blue">adequately</font>     funded and staffed and productive, we and Cytogen must be in <font color="blue">agreement</font> on     strategic and <font color="blue">operational matters</font></td>
    </tr>
    <tr>
      <td>There is a <font color="blue">significant</font> risk that, as a     result of differing views and priorities, there will be <font color="blue">occasions</font> when we do     not agree on various matters, as is the <font color="blue">case currently</font></td>
    </tr>
    <tr>
      <td>Our level of <font color="blue">commitment</font> to fund PSMA LLC and that of our joint venture     partner, Cytogen, is <font color="blue">based upon</font> a budget and work plan that are developed     and <font color="blue">approved annually by</font> the parties</td>
    </tr>
    <tr>
      <td>We have in the past experienced delays     in  reaching <font color="blue">agreement</font> with Cytogen regarding annual budget issues and     strategic and <font color="blue">operational matters</font> relating to PSMA LLC PSMA LLC currently     has no approved 2006 budget or work plan because we and Cytogen have not yet     reached <font color="blue">agreement</font> <font color="blue">with respect</font> to a number of matters relating to <font color="blue">PSMA LLC     </font>If we do not reach an <font color="blue">agreement</font> regarding the 2006 budget and work plan, we     <font color="blue">would likely</font> experience delays in advancing <font color="blue">the PSMA </font>programs and may need     to dissolve PSMA LLC and abandon <font color="blue">the PSMA </font>programs being <font color="blue">conducted by</font> PSMA     LLC We may not reach an <font color="blue">agreement</font> with Cytogen on these matters</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________       [48]Table of Contents     If we are unable to negotiate <font color="blue">collaborative</font> <font color="blue">agreement</font>s, our <font color="blue">cash burn rate</font>     <font color="blue">could increase</font> and our rate of product <font color="blue">development</font> could decrease</td>
    </tr>
    <tr>
      <td>Our business strategy includes as an element entering into <font color="blue">collaboration</font>s     <font color="blue">with pharmaceutical</font> and <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font> to develop and <font color="blue">commercialize</font>     our products and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We recently <font color="blue">entered into</font> such a <font color="blue">collaboration</font>     with Wyeth</td>
    </tr>
    <tr>
      <td>However, we may not be successful in negotiating <font color="blue">additional</font>     <font color="blue">collaborative</font>  <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">enter into</font> new <font color="blue">collaborative</font>     <font color="blue">arrangements</font>, we would have to devote more of our resources to clinical     product <font color="blue">development</font> and product-launch <font color="blue">activities</font>, and our <font color="blue">cash burn rate</font>     <font color="blue">would increase</font> or we would need to take steps to reduce our rate of product     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If we do not remedy our failure to achieve <font color="blue">milestones</font> or satisfy <font color="blue">conditions</font>     regarding some of our <font color="blue">product candidate</font>s, we may not maintain our rights     under our licenses relating to these <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>We  are  required to make substantial <font color="blue">cash payments</font>, achieve specified     <font color="blue">milestones</font> and satisfy other <font color="blue">conditions</font>, including filing for and obtaining     <font color="blue">marketing approval</font>s and <font color="blue">introducing products</font>, to maintain <font color="blue">rights under</font> our     <font color="blue"><font color="blue">intellectual</font> property</font> licenses</td>
    </tr>
    <tr>
      <td>Under our license <font color="blue">agreement</font>s with Sloan-Kettering Institute for Cancer     Research relating to GMK, we are required, among other things, to have filed     for  marketing  approval  for  a  drug  by  2000 and to have commenced     <font color="blue">commercialization</font> of the drug by 2002</td>
    </tr>
    <tr>
      <td>We have not achieved these and     other <font color="blue">milestones</font> and are unlikely to achieve them soon</td>
    </tr>
    <tr>
      <td>We are in a similar     position  with  respect  to our license <font color="blue">agreement</font> with <font color="blue">Antigenics Inc</font></td>
    </tr>
    <tr>
      <td><font color="blue">concerning</font>  QS-21^TM, a component of GMK If we can establish that our     failure to achieve these <font color="blue">milestones</font> resulted <font color="blue">from <font color="blue">technical issues</font> beyond</font>     our  control  or  delays  in <font color="blue">clinical studies</font> that could not have been     <font color="blue">reasonably avoided</font>, we may be entitled to a revision of these milestone     dates</td>
    </tr>
    <tr>
      <td>Although we believe that we <font color="blue">satisfy one</font> or more of these <font color="blue">conditions</font>,     we <font color="blue">may become involved</font> in <font color="blue">disputes with</font> our <font color="blue"><font color="blue">licensors</font> as</font> to our continued     right to a license</td>
    </tr>
    <tr>
      <td>In addition, at <font color="blue">September </font>1, 2004 we <font color="blue">became obligated</font>     under our license <font color="blue">agreement</font> with Columbia to pay Columbia dlra225cmam000</td>
    </tr>
    <tr>
      <td>We have     accrued this amount but, pending the outcome of <font color="blue">discussions with</font> <font color="blue"><font color="blue">Columbia  </font>   </font>regarding this payment and other matters relating to the license, we have     not yet paid it</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">comply with</font> our <font color="blue">obligations</font> under our license <font color="blue">agreement</font>s, the     <font color="blue">licensors</font> <font color="blue">may terminate</font> them</td>
    </tr>
    <tr>
      <td><font color="blue">Termination </font>of any of our <font color="blue">licenses could</font>     result  in  our  losing  our  rights to, and therefore being unable to     <font color="blue">commercialize</font>,  any  related  product</td>
    </tr>
    <tr>
      <td>We  have  had <font color="blue">discussions with</font>     Sloan-Kettering  and  <font color="blue">Columbia  </font>to  reach <font color="blue">agreement</font> on the revision of     applicable milestone dates</td>
    </tr>
    <tr>
      <td>We may not, however, reach <font color="blue">agreement</font> with these     <font color="blue">licensors</font> in a manner favorable to us</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">manufacturing</font> <font color="blue">capabilities</font>, <font color="blue">which could</font> <font color="blue">adversely</font> impact our     ability to <font color="blue">commercialize</font> products</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">manufacturing</font> <font color="blue">capabilities</font>, which may result in increased     costs of production or delay product <font color="blue">development</font> or <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In     order  to <font color="blue">commercialize</font> our <font color="blue">product candidate</font>s <font color="blue">successfully</font>, we or our     <font color="blue"><font color="blue">collaborator</font>s</font> must be able to <font color="blue">manufacture</font> products in <font color="blue">commercial quantities</font>,     in compliance with <font color="blue">regulatory</font> <font color="blue">requirements</font>, at acceptable costs and in a     <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of our <font color="blue">product candidate</font>s can be complex,     <font color="blue">difficult</font> to accomplish even in small quantities, <font color="blue">difficult</font> to scale-up for     large-scale production and subject to delays, inefficiencies and low yields     of <font color="blue">quality products</font></td>
    </tr>
    <tr>
      <td>The cost of <font color="blue">manufacturing</font> some of our <font color="blue">products may</font> make     <font color="blue">them prohibitively expensive</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate supplies</font> of any of our product     <font color="blue">candidates</font> or related materials are not available to us on a <font color="blue">timely basis</font> or     at  all,  our  <font color="blue"><font color="blue">clinical trials</font> could</font> be seriously delayed, since these     materials are time-consuming to <font color="blue">manufacture</font> and cannot be readily obtained     from third-party sources</td>
    </tr>
    <tr>
      <td>We  operate pilot-scale <font color="blue">manufacturing</font> <font color="blue">facilities</font> for the production of     vaccines and <font color="blue">recombinant proteins</font></td>
    </tr>
    <tr>
      <td>We believe that, for these types of     <font color="blue">product candidate</font>s, these <font color="blue"><font color="blue">facilities</font> will</font> be sufficient to meet our initial     needs for <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue"><font color="blue">facilities</font> may</font> be insufficient for     late-stage <font color="blue">clinical trials</font> for these types of <font color="blue">product candidate</font>s, and would     be insufficient for commercial-scale <font color="blue">manufacturing</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We may be     required to <font color="blue">expand further</font> our <font color="blue">manufacturing</font> staff and <font color="blue">facilities</font>, obtain     new <font color="blue">facilities</font> or contract with corporate <font color="blue"><font color="blue">collaborator</font>s</font> or other third     parties to <font color="blue">assist with production</font></td>
    </tr>
    <tr>
      <td>In the event that we decide to establish a commercial-scale <font color="blue">manufacturing</font>     <font color="blue">facility</font>, we will require substantial <font color="blue">additional</font> funds and will be required     to  hire  and  train  <font color="blue">significant</font> numbers of employees and <font color="blue">comply with</font>     applicable <font color="blue">regulations</font>, which are extensive</td>
    </tr>
    <tr>
      <td>We may not be able to build a     <font color="blue">manufacturing</font>  <font color="blue">facility</font> that both meets <font color="blue">regulatory</font> <font color="blue">requirements</font> and is     sufficient for our <font color="blue">clinical trials</font> or commercial-scale <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> <font color="blue">arrangements</font> with <font color="blue">third parties</font> for the <font color="blue">manufacture</font> of     some of our products</td>
    </tr>
    <tr>
      <td>Our third-party sourcing strategy may not result in a     cost-<font color="blue">effective</font> means for <font color="blue">manufacturing</font> products</td>
    </tr>
    <tr>
      <td>In employing third-party     <font color="blue">manufacture</font>rs,  we  will not control many aspects of the <font color="blue">manufacturing</font>     process, including <font color="blue">compliance by</font> these <font color="blue"><font color="blue">third parties</font> with</font> the FDA’s current     <font color="blue">Good Manufacturing Practices </font>and other <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We may not     be able to obtain <font color="blue">adequate supplies</font> from third-party <font color="blue">manufacture</font>rs in a     <font color="blue">timely fashion</font> for <font color="blue">development</font> or <font color="blue">commercialization</font> purposes, and commercial     quantities of <font color="blue">products may</font> not be available from contract <font color="blue">manufacture</font>rs at     acceptable costs</td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________       [49]Table of Contents     We are <font color="blue">dependent</font> on our patents and other <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>The     validity, <font color="blue">enforceability</font> and <font color="blue">commercial value</font> of these rights are highly     uncertain</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent</font> in part on obtaining, maintaining and enforcing     patent  and other <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of     <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">pharmaceutical firms</font> is <font color="blue">highly uncertain</font> and involves many     <font color="blue">complex legal</font> and <font color="blue">technical issues</font></td>
    </tr>
    <tr>
      <td>There is <font color="blue">no clear policy involving</font> the     breadth of claims allowed, or the degree of protection afforded, under     patents in this area</td>
    </tr>
    <tr>
      <td>Accordingly, the patent <font color="blue">applications</font> owned by or     licensed to us may not result in patents being issued</td>
    </tr>
    <tr>
      <td>We are aware of other     groups that have patent <font color="blue">applications</font> or patents containing claims similar to     or overlapping those in our patents and patent <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>We do not     expect to know for <font color="blue">several years</font> the <font color="blue">relative strength</font> or scope of our     <font color="blue">patent position</font> as compared to these other groups</td>
    </tr>
    <tr>
      <td>Furthermore, patents that     we  own  or  license  may  not  <font color="blue">enable us</font> to preclude <font color="blue">competitors</font> from     <font color="blue">commercializing</font>  drugs,  and  <font color="blue">consequently</font> may not <font color="blue">provide us with</font> any     <font color="blue">meaningful competitive advantage</font></td>
    </tr>
    <tr>
      <td>We own or have licenses to <font color="blue">several issued patents</font></td>
    </tr>
    <tr>
      <td>However, the issuance of     a  patent  is not <font color="blue">conclusive</font> as to its validity or <font color="blue">enforceability</font></td>
    </tr>
    <tr>
      <td>The     validity or <font color="blue">enforceability</font> of a patent after its <font color="blue">issuance by</font> the patent     office can be challenged in <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patents may</font> be <font color="blue">successfully</font>     challenged</td>
    </tr>
    <tr>
      <td>Moreover, we may incur substantial costs in <font color="blue">litigation</font> to uphold     the  validity of patents or to <font color="blue">prevent infringement</font></td>
    </tr>
    <tr>
      <td>If the outcome of     <font color="blue">litigation</font> is adverse to us, <font color="blue">third parties</font> may be able to use our patented     invention without payment to us</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue"><font color="blue">third parties</font> may avoid</font> our     <font color="blue">patents through design innovation</font></td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">product candidate</font>s, including MNTX, PRO 140, GMK and our PSMA     program products, incorporate to some degree <font color="blue"><font color="blue">intellectual</font> property</font> licensed     <font color="blue">from <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>We can lose the right to patents and other <font color="blue">intellectual</font>     <font color="blue">property licensed</font> to us if the related license <font color="blue">agreement</font> is <font color="blue">terminated due</font>     to a <font color="blue">breach by us</font> or otherwise</td>
    </tr>
    <tr>
      <td>Our ability, and that of our <font color="blue">collaboration</font>     partners, to <font color="blue">commercialize</font> products incorporating licensed <font color="blue">intellectual</font>     property  would  be  impaired  if  the related license <font color="blue">agreement</font>s were     terminated</td>
    </tr>
    <tr>
      <td>Generally, we have the right to defend and <font color="blue">enforce <font color="blue">patents licensed</font> by us</font>,     either in the <font color="blue">first instance</font> or if the <font color="blue">licensor chooses</font> not to do so</td>
    </tr>
    <tr>
      <td>In     addition, our license <font color="blue">agreement</font> with the <font color="blue">University of Chicago </font>regarding     MNTX gives us the right to prosecute and maintain the <font color="blue">licensed patents</font></td>
    </tr>
    <tr>
      <td>We     bear the cost of engaging in some or all of these <font color="blue">activities</font> <font color="blue">with respect</font> to     our license <font color="blue">agreement</font>s with Sloan-Kettering for GMK and the University of     Chicago for MNTX  Under our Collaboration Agreement, Wyeth has the right,     at its expense, to defend and enforce the MNTX <font color="blue">patents licensed</font> to Wyeth by     us</td>
    </tr>
    <tr>
      <td>With most of our other license <font color="blue">agreement</font>s, the <font color="blue">licensor bears</font> the cost     of engaging in all of these <font color="blue">activities</font>, although we may share in those costs     <font color="blue">under specified circumstances</font></td>
    </tr>
    <tr>
      <td>Historically, our costs of <font color="blue">defending patent</font>     rights, both our own and those we license, have not been material</td>
    </tr>
    <tr>
      <td>We  also rely on unpatented <font color="blue">technology</font>, trade secrets and <font color="blue">confidential</font>     information</td>
    </tr>
    <tr>
      <td>Third  parties  may  in<font color="blue">dependent</font>ly develop <font color="blue">substantially</font>     equivalent  information and <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our     <font color="blue">technology</font> or disclose our <font color="blue">technology</font>, and we may be unable to <font color="blue">effective</font>ly     protect our rights in unpatented <font color="blue">technology</font>, trade secrets and <font color="blue">confidential</font>     information</td>
    </tr>
    <tr>
      <td>We require each of our employees, consultants and advisors to     execute a <font color="blue">confidential</font>ity <font color="blue">agreement</font> at the <font color="blue">commencement</font> of an <font color="blue">employment</font> or     consulting <font color="blue"><font color="blue">relationship</font> with</font> us</td>
    </tr>
    <tr>
      <td>However, these <font color="blue">agreement</font>s may not provide     <font color="blue">effective</font> protection in the event of <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> of     <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>If we infringe third-party patent or other <font color="blue"><font color="blue">intellectual</font> property</font> rights, we     may need to alter or terminate a product <font color="blue">development</font> program</td>
    </tr>
    <tr>
      <td>There may be patent or other <font color="blue"><font color="blue">intellectual</font> property</font> rights belonging to     others that require us to alter our products, pay licensing fees or cease     certain <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">products infringe patent</font> or other <font color="blue">intellectual</font>     <font color="blue">property rights</font> of others, the owners of those <font color="blue">rights could bring legal</font>     <font color="blue">actions <font color="blue">against us</font></font> claiming damages and seeking to enjoin <font color="blue">manufacturing</font> and     marketing of the <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">legal actions</font> are successful,     in addition to any <font color="blue">potential <font color="blue">liability</font></font> for damages, we could be required to     obtain a license in order to continue to <font color="blue">manufacture</font> or market the affected     products</td>
    </tr>
    <tr>
      <td>We may not prevail in any <font color="blue">action brought <font color="blue">against us</font></font>, and any     license required under any rights that we <font color="blue">infringe may</font> not be <font color="blue">available on</font>     acceptable terms or at all</td>
    </tr>
    <tr>
      <td>We are aware of <font color="blue"><font color="blue">intellectual</font> property</font> rights     held  by  <font color="blue">third parties</font> that relate to products or <font color="blue">technologies</font> we are     developing</td>
    </tr>
    <tr>
      <td>For  example,  we are aware of other groups investigating     <font color="blue">methylnaltrexone</font> and other peripheral <font color="blue">opioid <font color="blue">antagonist</font></font>s, PSMA or related     compounds and CCR5 <font color="blue">monoclonal antibodies</font> and of patents held, and patent     <font color="blue">applications</font> filed, by these groups in those areas</td>
    </tr>
    <tr>
      <td>While the validity of     these issued patents, <font color="blue">patentability</font> of these pending patent <font color="blue">applications</font> and     <font color="blue">applicability</font> of any of them to our programs are uncertain, if asserted     <font color="blue">against us</font>, any related patent or other <font color="blue"><font color="blue">intellectual</font> property</font> rights could     <font color="blue">adversely</font> affect our ability to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>The research, <font color="blue">development</font> and <font color="blue">commercialization</font> of a <font color="blue"><font color="blue">biopharmaceutical</font> often</font>     involve alternative <font color="blue">development</font> and optimization routes, which are presented     <font color="blue">at various stages</font> in the <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td>The <font color="blue">preferred routes cannot</font> be     <font color="blue">predicted at</font> the outset of a research and <font color="blue">development</font> program because they     <font color="blue">will <font color="blue">depend on</font></font> subsequent discoveries and test results</td>
    </tr>
    <tr>
      <td>There are numerous     third-party patents in our field, and we may need to obtain a license to a     patent in order to pursue the preferred <font color="blue">development</font> route of one or more of     our products</td>
    </tr>
    <tr>
      <td>The need to obtain a <font color="blue">license would decrease</font> the ultimate     <font color="blue">profitability</font> of the <font color="blue">applicable product</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot negotiate</font> a license,     we might have to pursue a less desirable <font color="blue">development</font> route or terminate the     <font color="blue">program altogether</font></td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________       [50]Table of Contents     We  are <font color="blue">dependent</font> upon <font color="blue">third parties</font> for a variety of functions</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">arrangements</font> may not <font color="blue">provide us with</font> the benefits we expect</td>
    </tr>
    <tr>
      <td>We rely in part on <font color="blue">third parties</font> to perform a variety of functions</td>
    </tr>
    <tr>
      <td>We are     party to numerous <font color="blue">agreement</font>s which place substantial <font color="blue">responsibility</font> on     clinical research organizations, consultants and other <font color="blue">service providers</font> for     the  <font color="blue">development</font> of our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on medical</font> and academic     <font color="blue"><font color="blue">institution</font>s</font>  to  perform  aspects  of  our <font color="blue">clinical trials</font> of product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In addition, an element of our research and <font color="blue">development</font> strategy     is  to  in-license <font color="blue">technology</font> and <font color="blue">product candidate</font>s from academic and     <font color="blue">government</font> <font color="blue"><font color="blue">institution</font>s</font> in order to <font color="blue">minimize <font color="blue">investment</font>s</font> in <font color="blue">early research</font></td>
    </tr>
    <tr>
      <td>Furthermore, we recently <font color="blue">entered into</font> an <font color="blue">agreement</font> under which we will     <font color="blue">depend on</font> Wyeth for the <font color="blue">commercialization</font> and <font color="blue">development</font> of MNTX, our lead     <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>We may not be able to maintain any of these <font color="blue">relationship</font>s     or <font color="blue">establish new ones on <font color="blue">beneficial</font> terms</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may not be able     to enter new <font color="blue">arrangements</font> without undue delays or <font color="blue">expenditures</font>, and these     <font color="blue">arrangements</font> may not allow us to compete <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">lack sales</font> and marketing experience, <font color="blue">which will</font> make us <font color="blue">dependent</font> on     <font color="blue">third parties</font> for their expertise in this area</td>
    </tr>
    <tr>
      <td>We have no experience in sales, marketing or <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>If we receive     <font color="blue">marketing approval</font>, we expect to market and sell our <font color="blue">products principally</font>     through <font color="blue">distribution</font>, co-marketing, co-promotion or licensing <font color="blue">arrangements</font>     with <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We may also consider <font color="blue">contracting with</font> a <font color="blue">third party</font>     <font color="blue">professional pharmaceutical detailing</font> and <font color="blue">sales organization</font> to perform the     <font color="blue">marketing function</font> for our products</td>
    </tr>
    <tr>
      <td>Under our license and co-<font color="blue">development</font>     <font color="blue">agreement</font> with Wyeth, Wyeth is responsible for <font color="blue">commercializing</font> MNTX To the     extent  that  we  <font color="blue">enter into</font> <font color="blue">distribution</font>, co-marketing, co-promotion,     detailing or licensing <font color="blue">arrangements</font> for the marketing and sale of our other     products, any revenues we receive <font color="blue">will depend primarily on</font> the efforts of     third  parties</td>
    </tr>
    <tr>
      <td>We will not control the amount and timing of marketing     resources these <font color="blue">third parties</font> devote to our products</td>
    </tr>
    <tr>
      <td>In addition, if we     market products directly, <font color="blue">significant</font> <font color="blue">additional</font> <font color="blue">expenditures</font> and <font color="blue">management</font>     <font color="blue">resources would</font> be required to develop an <font color="blue">internal sales force</font></td>
    </tr>
    <tr>
      <td>We may not     be able to establish a <font color="blue">successful sales force should</font> we choose to do so</td>
    </tr>
    <tr>
      <td>If we lose key <font color="blue">management</font> and <font color="blue"><font color="blue">scientific personnel</font> on whom</font> we depend, our     business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>We  are <font color="blue">dependent</font> upon our key <font color="blue">management</font> and <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>Paul J Maddon, our <font color="blue">Chief Executive Officer </font>and     Chief Science Officer, could cause our <font color="blue">management</font> and <font color="blue">operations</font> to suffer</td>
    </tr>
    <tr>
      <td>We have an <font color="blue">employment</font> <font color="blue">agreement</font> with Dr</td>
    </tr>
    <tr>
      <td>Maddon, the initial term of which     ran through June 30, 2005, which was <font color="blue">automatically renewed</font> for an <font color="blue">additional</font>     period of two years</td>
    </tr>
    <tr>
      <td>Executive Compensation - <font color="blue">Employment </font>    Agreements” in this <font color="blue">Annual Report </font>on Form 10-K for the year ended <font color="blue">December </font>    31, 2005</td>
    </tr>
    <tr>
      <td>We are currently in <font color="blue">discussions with</font> Dr</td>
    </tr>
    <tr>
      <td>Maddon regarding the     <font color="blue">future renewal</font> of his <font color="blue">employment</font> <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Employment </font><font color="blue">agreement</font>s do not,     however, assure the continued <font color="blue">employment</font> of an employee</td>
    </tr>
    <tr>
      <td>We maintain key-man     <font color="blue">life insurance on</font> Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for qualified employees among companies in the <font color="blue">biopharmaceutical</font>     industry is intense</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success</font> depends upon our ability to attract,     retain and <font color="blue">motivate highly skilled employees</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">commercialize</font> our     products  <font color="blue">successfully</font>, we may be required to expand <font color="blue">substantially</font> our     personnel, particularly in the areas of <font color="blue">manufacturing</font>, <font color="blue">clinical trials</font>     <font color="blue">management</font>, <font color="blue">regulatory</font> affairs, business <font color="blue">development</font> and marketing</td>
    </tr>
    <tr>
      <td>We may     not be successful in hiring or retaining <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>If  we  are unable to obtain <font color="blue">sufficient quantities</font> of the raw and bulk     materials  needed  to  make  our products, our product <font color="blue">development</font> and     <font color="blue">commercialization</font> could be slowed or stopped</td>
    </tr>
    <tr>
      <td>We currently obtain supplies of <font color="blue">critical raw materials used</font> in production of     MNTX,  GMK and other of our <font color="blue">product candidate</font>s from single sources</td>
    </tr>
    <tr>
      <td>In     particular, we rely on single-source third-party <font color="blue">manufacture</font>rs for the     supply of both bulk and finished form MNTX We have a supply <font color="blue">agreement</font> with     Mallinckrodt Inc, our <font color="blue">current supplier</font> of bulk-form MNTX, which has an     initial  term  that <font color="blue">expires on</font> January 1, 2008</td>
    </tr>
    <tr>
      <td>In <font color="blue">accordance with</font> our     <font color="blue">collaboration</font> <font color="blue">agreement</font> with Wyeth, we <font color="blue">will transfer</font> to Wyeth, at a mutually     agreeable time, the <font color="blue">responsibility</font> for <font color="blue">manufacturing</font> MNTX for clinical and     <font color="blue">commercial use</font>, including our supply <font color="blue">agreement</font>s with <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We do     not have long-term contracts with any of our other suppliers</td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">commercialization</font> of GMK requires an adjuvant, QS-21^TM, <font color="blue">available on</font>ly from     <font color="blue">Antigenics Inc</font></td>
    </tr>
    <tr>
      <td>Our existing <font color="blue">arrangements</font> may not result in the supply of     <font color="blue">sufficient quantities</font> of our <font color="blue">product candidate</font>s needed to accomplish our     clinical <font color="blue">development</font> programs, and we may not have the right or <font color="blue">capability</font>     to <font color="blue">manufacture</font> <font color="blue">sufficient quantities</font> of these products to meet our needs if     our suppliers are unable or unwilling to do so</td>
    </tr>
    <tr>
      <td>Any delay or <font color="blue">disruption</font> in     the <font color="blue">availability</font> of <font color="blue">raw materials would slow</font> or stop product <font color="blue">development</font> and     <font color="blue">commercialization</font> of the <font color="blue">relevant product</font>           27       _________________________________________________________________       [51]Table of Contents     A substantial portion of our <font color="blue">funding comes from federal <font color="blue"><font color="blue">government</font> grants</font></font>     and <font color="blue">research contracts</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot rely on</font> these grants or <font color="blue">contracts as</font> a     <font color="blue">continuing source</font> of funds</td>
    </tr>
    <tr>
      <td>A substantial portion of our revenues to date has <font color="blue">been derived from federal</font>     <font color="blue"><font color="blue">government</font> grants</font> and <font color="blue">research contracts</font></td>
    </tr>
    <tr>
      <td>In July and <font color="blue">September </font>2005, we     were  awarded a dlra3dtta0 million and a dlra10dtta1 million grant from the NIH to     partially fund our <font color="blue">hepatitis</font> C virus and PRO 140 programs, respectively</td>
    </tr>
    <tr>
      <td>Also, in 2004 we were awarded, in the aggregate, approximately dlra9dtta2 million     in NIH grants and <font color="blue">research contracts</font> in addition to previous years’ awards</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot rely on</font> grants or <font color="blue">additional</font> <font color="blue">contracts as</font> a <font color="blue">continuing source</font> of     funds</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">funds available under</font> these grants and <font color="blue">contracts must</font> be     <font color="blue">applied by us toward</font> the research and <font color="blue">development</font> programs specified by the     <font color="blue"><font color="blue">government</font> rather than</font> for all our <font color="blue">programs <font color="blue">generally</font></font></td>
    </tr>
    <tr>
      <td>For example, the     dlra28dtta6 million contract awarded to us by the NIH in <font color="blue">September </font>2003 must be     <font color="blue">used by us</font> in furtherance of our efforts to develop an HIV vaccine</td>
    </tr>
    <tr>
      <td>The     <font color="blue">government</font>’s obligation to make <font color="blue">payments under</font> these grants and contracts is     subject to <font color="blue">appropriation by</font> the US <font color="blue">Congress </font>for funding in each year</td>
    </tr>
    <tr>
      <td>Moreover, it is possible that <font color="blue">Congress </font>or the <font color="blue"><font color="blue">government</font> agencies</font> that     <font color="blue">administer</font> these <font color="blue"><font color="blue">government</font> research programs will decide</font> to scale back     these programs or <font color="blue">terminate them due</font> to their own <font color="blue">budgetary constraints</font></td>
    </tr>
    <tr>
      <td>Additionally, these grants and <font color="blue">research contracts</font> are subject to <font color="blue">adjustment</font>     based  upon  the results of <font color="blue">periodic audits</font> performed on behalf of the     <font color="blue">granting authority</font></td>
    </tr>
    <tr>
      <td>Consequently, the <font color="blue">government</font> may not award grants or     <font color="blue">research contracts</font> to us in the future, and any amounts that we <font color="blue">derive from</font>     <font color="blue">existing grants</font> or <font color="blue">contracts may</font> be less than those received to date</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">health care</font> reform measures</font> are enacted, our operating results and our     ability to <font color="blue">commercialize</font> products could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, there have <font color="blue">been numerous proposals</font> to change the health     care  system  in  the US and in <font color="blue">foreign jurisdictions</font></td>
    </tr>
    <tr>
      <td>Some of these     proposals have included measures that would limit or eliminate payments for     medical procedures and <font color="blue">treatments</font> or subject the pricing of <font color="blue">pharmaceuticals</font>     to <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>In some foreign countries, particularly countries of     the European Union, the pricing of <font color="blue">prescription</font> <font color="blue">pharmaceuticals</font> is subject     to <font color="blue">government</font>al control</td>
    </tr>
    <tr>
      <td>In addition, as a result of the <font color="blue">trend towards</font>     <font color="blue">managed <font color="blue">health care</font></font> in the US, <font color="blue">as well as legislative proposals</font> to reduce     <font color="blue">government</font>  insurance  programs,  third-party  payors are <font color="blue">increasingly</font>     attempting to <font color="blue">contain <font color="blue">health care</font> costs by limiting both coverage</font> and the     level of <font color="blue">reimbursement</font> of <font color="blue">new drug products</font></td>
    </tr>
    <tr>
      <td>Consequently, <font color="blue">significant</font>     un<font color="blue">certainty</font> exists as to the <font color="blue">reimbursement</font> status of <font color="blue">newly approved health</font>     <font color="blue">care products</font></td>
    </tr>
    <tr>
      <td>If we or any of our <font color="blue"><font color="blue">collaborator</font>s</font> succeed in <font color="blue">bringing one</font> or more of our     products to market, third-party payors may establish and maintain price     levels  insufficient  for  us  to realize an <font color="blue">appropriate return on</font> our     <font color="blue">investment</font> in product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>changes in the <font color="blue">health care</font>     system in the US or elsewhere, including changes resulting from adverse     trends in third-party <font color="blue">reimbursement</font> programs, could have a material adverse     effect  on  our operating results and our ability to <font color="blue">raise capital</font> and     <font color="blue">commercialize</font> products</td>
    </tr>
    <tr>
      <td>We are exposed to <font color="blue">product <font color="blue">liability</font></font> claims, and in the future we may not be     able to obtain <font color="blue">insurance against</font> these claims at a <font color="blue">reasonable cost</font> or at     all</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">exposes us</font> to <font color="blue">product <font color="blue">liability</font></font> risks, which are inherent in     the testing, <font color="blue">manufacturing</font>, marketing and sale of <font color="blue">pharmaceutical products</font></td>
    </tr>
    <tr>
      <td>We  may  not be able to avoid <font color="blue">product <font color="blue">liability</font></font> exposure</td>
    </tr>
    <tr>
      <td>If a product     <font color="blue">liability</font> claim is <font color="blue">successfully</font> brought <font color="blue">against us</font>, our financial position     may be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> insurance for the <font color="blue">biopharmaceutical</font> industry is <font color="blue">generally</font>     expensive,  when  <font color="blue">available at</font> all</td>
    </tr>
    <tr>
      <td>We have obtained <font color="blue">product <font color="blue">liability</font></font>     insurance  in  the amount of dlra5dtta0 million per occurrence, subject to a     deductible and a dlra5dtta0 million annual aggregate limitation</td>
    </tr>
    <tr>
      <td>In addition,     where  local  <font color="blue">statutory <font color="blue">requirements</font> exceed</font> the limits of our existing     insurance or where <font color="blue">local policies</font> of insurance are required, we maintain     <font color="blue">additional</font> clinical trial <font color="blue">liability</font> insurance to meet these <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">present insurance coverage may</font> not be adequate to cover claims brought     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>In addition, some of our license and other <font color="blue">agreement</font>s require us     to obtain <font color="blue">product <font color="blue">liability</font></font> insurance</td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>insurance coverage may not     be available to us at a <font color="blue">reasonable cost</font> in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">handle hazardous materials</font> and must <font color="blue">comply with</font> environmental laws and     <font color="blue">regulations</font>, which can be expensive and <font color="blue">restrict how</font> we do business</td>
    </tr>
    <tr>
      <td>If we     are involved in a <font color="blue">hazardous waste spill</font> or other <font color="blue">accident</font>, we could be     liable for damages, penalties or other forms of censure</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> work and <font color="blue">manufacturing</font> processes involve the     use of hazardous, controlled and <font color="blue">radioactive materials</font></td>
    </tr>
    <tr>
      <td>We are subject to     federal,  state  and  local  laws  and  <font color="blue">regulations</font> governing the use,     <font color="blue">manufacture</font>, storage, handling and disposal of these materials</td>
    </tr>
    <tr>
      <td><font color="blue">Despite     </font>procedures that we implement for handling and disposing of these materials,     we <font color="blue">cannot eliminate</font> the risk of <font color="blue">accident</font>al contamination or injury</td>
    </tr>
    <tr>
      <td>In the     event of a <font color="blue">hazardous waste spill</font> or other <font color="blue">accident</font>, we could be liable for     damages,  penalties  or other forms of censure</td>
    </tr>
    <tr>
      <td>In addition, we may be     required to incur <font color="blue">significant</font> costs to <font color="blue">comply with</font> environmental laws and     <font color="blue">regulations</font> in the future</td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________       [52]Table of Contents     Our  stock  price  has a history of <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>You should consider an     <font color="blue">investment</font> in our <font color="blue">stock as risky</font> and <font color="blue">invest only</font> if you can withstand a     <font color="blue">significant</font> loss</td>
    </tr>
    <tr>
      <td>Our stock price has a history of <font color="blue">significant</font> <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td><font color="blue">Between January </font>1,     2002 and <font color="blue">December </font>31, 2005, our stock price has ranged from dlra3dtta82 to dlra27dtta00     per share</td>
    </tr>
    <tr>
      <td>At times, our stock price has <font color="blue">been volatile even</font> in the absence     of <font color="blue">significant</font> news or <font color="blue">development</font>s relating to us</td>
    </tr>
    <tr>
      <td>Moreover, the stocks of     <font color="blue"><font color="blue">bio<font color="blue">technology</font></font> companies</font> and the stock market <font color="blue">generally</font> have been subject to     <font color="blue">dramatic price swings</font> in <font color="blue">recent years</font></td>
    </tr>
    <tr>
      <td>Factors that may have a <font color="blue">significant</font>     <font color="blue">impact on</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font> include:                                               ·       the results of <font color="blue">clinical trials</font> and pre<font color="blue">clinical studies</font> involving our     products or those of our <font color="blue">competitors</font>;                                                ·       changes in the status of any of our drug <font color="blue">development</font> programs, including     delays in <font color="blue">clinical trials</font> or program <font color="blue">termination</font>s;                                                ·       <font color="blue">development</font>s regarding our efforts to achieve <font color="blue">marketing approval</font> for our     products;                                                ·       <font color="blue">development</font>s in our <font color="blue"><font color="blue">relationship</font> with</font> Wyeth regarding the <font color="blue">development</font> and     <font color="blue">commercialization</font> of MNTX;                                                ·       <font color="blue">announcements</font> of <font color="blue">technological</font> innovations or new <font color="blue">commercial product</font>s by us,     our <font color="blue"><font color="blue">collaborator</font>s</font> or our <font color="blue">competitors</font>;                                                ·       <font color="blue">development</font>s in our <font color="blue">relationship</font>s with other <font color="blue">collaborative</font> partners;                                                ·       <font color="blue">development</font>s in patent or other <font color="blue">proprietary rights</font>;                                                ·       <font color="blue">government</font>al regulation;                                                ·       changes in <font color="blue">reimbursement</font> policies or <font color="blue">health care</font> legislation;                                                ·       public concern as to the safety and efficacy of products developed by us,     our <font color="blue"><font color="blue">collaborator</font>s</font> or our <font color="blue">competitors</font>;                                                ·       our ability to fund on-going <font color="blue">operations</font>;                                                ·       <font color="blue">fluctuations</font> in our operating results; and                                                ·       general market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">principal <font color="blue">stockholders</font></font> are able to exert <font color="blue">significant</font> influence over     <font color="blue">matters submitted</font> to <font color="blue">stockholders</font> for approval</td>
    </tr>
    <tr>
      <td>At <font color="blue">December </font>31, 2005, Dr</td>
    </tr>
    <tr>
      <td>Maddon and <font color="blue">stockholders</font> <font color="blue">affiliated</font> with Tudor     Investment Corporation <font color="blue">together <font color="blue">beneficial</font>ly</font> own or <font color="blue">control approximately</font>     19prca of our <font color="blue">outstanding shares</font> of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>These persons, should they     choose to act together, could exert <font color="blue">significant</font> influence in determining the     outcome of <font color="blue">corporate actions</font> requiring <font color="blue">stockholder approval</font> and otherwise     control our business</td>
    </tr>
    <tr>
      <td>This control could have the effect of delaying or     preventing a change in control of us and, <font color="blue">consequently</font>, could <font color="blue">adversely</font>     affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Anti-takeover <font color="blue">provisions may</font> make the removal of our <font color="blue">Board of Directors </font>or     <font color="blue">management</font> more <font color="blue">difficult</font> and discourage hostile bids for control of our     company that may be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">Board of Directors </font>is authorized, without further stockholder action, to     issue from time to time shares of <font color="blue">preferred stock</font> in one or more designated     series or classes</td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock</font>, as well as provisions in     certain of our <font color="blue">stock options</font> that provide for <font color="blue">acceleration</font> of <font color="blue">exercisability</font>     upon  a change of control, and Section 203 and other provisions of the     <font color="blue">Delaware General Corporation Law </font>could:                                                ·       make the takeover of <font color="blue">Progenics </font>or the removal of our <font color="blue">Board of Directors </font>or     <font color="blue">management</font> more <font color="blue">difficult</font>;                                                ·       discourage hostile bids for control of <font color="blue">Progenics </font>in which <font color="blue">stockholders</font> may     receive a premium for their shares of <font color="blue">common stock</font>; and                                                 ·       otherwise dilute the rights of holders of our <font color="blue">common stock</font> and depress the     <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>29       _________________________________________________________________       [53]Table of Contents     If there are substantial sales of our <font color="blue">common stock</font>, the <font color="blue">market price</font> of our     <font color="blue">common stock</font> could decline</td>
    </tr>
    <tr>
      <td>Sales of substantial numbers of shares of <font color="blue">common stock</font> could cause a decline     in the <font color="blue">market price</font> of our stock</td>
    </tr>
    <tr>
      <td>We require substantial <font color="blue">external funding</font> to     finance our research and <font color="blue">development</font> programs and <font color="blue">may seek such funding</font>     through the issuance and sale of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have announced that we     have <font color="blue">filed shelf <font color="blue">registration</font> statements</font> to permit the sale of up to 4dtta0     <font color="blue">million shares</font> of our <font color="blue">common stock</font> to investors and to permit the public     reoffer and sale from time to time of up to 286cmam000 shares of our common     stock by certain <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Sales of our <font color="blue">common stock</font> pursuant to these     <font color="blue">registration</font>  statements  could cause the <font color="blue">market price</font> or our stock to     decline</td>
    </tr>
    <tr>
      <td>In addition, some of our other <font color="blue">stockholders</font> are entitled to require     us to register their shares of <font color="blue">common stock</font> for offer or sale to the public</td>
    </tr>
    <tr>
      <td>Also, we have filed Form S-8 <font color="blue">registration</font> statements registering shares     <font color="blue">issuable pursuant</font> to our <font color="blue">equity compensation</font> plans</td>
    </tr>
    <tr>
      <td>Any <font color="blue">sales by existing</font>     <font color="blue">stockholders</font> or holders of <font color="blue">options may</font> have an adverse effect on our ability     to <font color="blue">raise capital</font> and may <font color="blue">adversely</font> affect the <font color="blue">market price</font> of our common     stock</td>
    </tr>
  </tbody>
</table>